SCHEMBL30150593

SCHEMBL30150593

c1ccc(COc2cccnc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.62
MAPT P10636 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
MAPK1 P28482 2/20 0.61
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
NOS1 P29475 1/20 0.54
NOS2 P35228 1/20 0.54
GRM2 Q14416 1/20 0.52
CHRNB2 P17787 2/20 0.51
CHRNA4 P43681 2/20 0.51
P4HTM Q9NXG6 1/20 0.51
HTR1A P08908 1/20 0.51
DRD2 P14416 1/20 0.51
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1323646 1.00 RAB9A (0.62) RAB9AMAPTNPSR1MAPK1MEN1
Bromide SCHEMBL27462942 0.98 RAB9A (0.60) RAB9AMAPTNPSR1MAPK1MEN1
Pyridine SCHEMBL5787948 0.96 RAB9A (0.59) RAB9AMAPTNPSR1MAPK1MEN1
SCHEMBL6238551 0.92 RAB9A (0.55) RAB9AMAPTNPSR1MAPK1MEN1
Acetic Acid SCHEMBL27351298 0.90 KMT2A (0.58) RAB9AMAPTNPSR1MAPK1MEN1
SCHEMBL7539917 0.90 RAB9A (0.60) RAB9AMAPTNPSR1MAPK1MEN1
SCHEMBL7311175 0.89 MAPK1 (0.65) RAB9AMAPK1MEN1KMT2AGRM2
SCHEMBL4313839 0.88 MAPK1 (0.61) RAB9AMAPTNPSR1MAPK1MEN1
Ethoxycarbonyl Group SCHEMBL27686480 0.84 RAB9A (0.51) RAB9AMAPTNPSR1MAPK1MEN1
SCHEMBL24932986 0.84 RAB9A (0.61) RAB9AMAPTNPSR1MAPK1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2024-04-11 US disclosed
US-20220402873-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES AUTOTAC INC. (KR) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ADORA3, ADORA2A, ADORA2B RAB9A 1647/4885MAPT 4779/4885NPSR1 116/4885
US-20220402873-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES SQSTM1, ATG7, ATG13 RAB9A 217/4885MAPT 345/4885NPSR1 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.